Skip to content

TriangleGet started

← Full study record

NCT00602667 · OUTCOME

Concentration of Cerebrospinal Fluid Neurotransmitters

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma · Source last updated 2026-05-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: ng/ml
Interval / dispersion: Full Range
Time frame: Baseline, at the completion of therapy, and every 12 months up to 36 months after off therapy date

What was measured

Concentrations of various neurotransmitters in cerebrospinal fluid were measured at 5 timepoints. The median concentration of each neurotransmitter at each time point was calculated and provided with a full range.

Analysis population: Eligible patients who had cerebrospinal fluid neurotransmitter studies performed. Seventeen patients had studies performed.

Groups in this outcome

Patients With Neurotransmitter Studies

Patients with neurotransmitter studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	17

Reported measurements

Dopamine concentration at baseline

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	12

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	3.16	Not reported	0.18	4586.18	Not reported

Dopamine concentration at completion of treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	12

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	3.70	Not reported	0.82	39.16	Not reported

Dopamine concentration at 12 months off treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	11

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	6.43	Not reported	2.20	486.46	Not reported

Dopamine concentration at 24 months off treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	14

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	4.46	Not reported	0.04	1093.28	Not reported

Dopamine concentration at 36 months off treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	5

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	4.05	Not reported	0.11	9.32	Not reported

3,4-dihydroxyphenylacetic acid concentration at baseline

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	15

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	2.56	Not reported	0.91	11.24	Not reported

3,4-dihydroxyphenylacetic acid concentration at completion of treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	14

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	1.62	Not reported	0.82	9.91	Not reported

3,4-dihydroxyphenylacetic acid concentration at 12 months off treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	15

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	1.04	Not reported	0.51	6.55	Not reported

3,4-dihydroxyphenylacetic acid concentration at 24 months off treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	14

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	1.52	Not reported	0.31	6.70	Not reported

3,4-dihydroxyphenylacetic acid concentration at 36 months off treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	9

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	1.00	Not reported	0.38	3.10	Not reported

Hydroxytryptamine concentration at baseline

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	14

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	2.38	Not reported	0.12	13.94	Not reported

Hydroxytryptamine concentration at completion of treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	13

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	2.01	Not reported	0.06	15.01	Not reported

Hydroxytryptamine concentration at 12 months off treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	17

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	2.00	Not reported	0.06	8.46	Not reported

Hydroxytryptamine concentration at 24 months off treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	16

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	2.44	Not reported	1.01	7.70	Not reported

Hydroxytryptamine concentration at 36 months off treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	9

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	1.62	Not reported	0.29	8.85	Not reported

Hydroxyindoleacetic acid concentration at baseline

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	17

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	52.03	Not reported	30.02	400.35	Not reported

Hydroxyindoleacetic acid concentration at completion of treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	17

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	52.72	Not reported	27.42	110.24	Not reported

Hydroxyindoleacetic acid concentration at 12 months off treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	17

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	35.72	Not reported	24.58	51.60	Not reported

Hydroxyindoleacetic acid concentration at 24 months off treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	17

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	33.98	Not reported	25.69	45.63	Not reported

Hydroxyindoleacetic acid concentration at 36 months off treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	9

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	31.56	Not reported	16.09	53.04	Not reported

Homovanillic acid concentration at baseline

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	17

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	82.44	Not reported	34.57	565.30	Not reported

Homovanillic acid concentration at completion of treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	17

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	114.13	Not reported	73.43	179.21	Not reported

Homovanillic acid concentration at 12 months off treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	17

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	68.28	Not reported	40.78	146.84	Not reported

Homovanillic acid concentration at 24 months off treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	17

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	88.27	Not reported	55.27	166.99	Not reported

Homovanillic acid concentration at 36 months off treatment

Analysis denominator · Participants

Group	Source count
Patients With Neurotransmitter Studies	9

Values in ng/ml · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Patients With Neurotransmitter Studies	79.78	Not reported	35.40	152.51	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
0.18
upper Limit
4586.18
value
3.16
denoms
counts
group Id
OG000
value
12
units
Participants
title
Dopamine concentration at baseline
categories
measurements
group Id
OG000
lower Limit
0.82
upper Limit
39.16
value
3.70
denoms
counts
group Id
OG000
value
12
units
Participants
title
Dopamine concentration at completion of treatment
categories
measurements
group Id
OG000
lower Limit
2.20
upper Limit
486.46
value
6.43
denoms
counts
group Id
OG000
value
11
units
Participants
title
Dopamine concentration at 12 months off treatment
categories
measurements
group Id
OG000
lower Limit
0.04
upper Limit
1093.28
value
4.46
denoms
counts
group Id
OG000
value
14
units
Participants
title
Dopamine concentration at 24 months off treatment
categories
measurements
group Id
OG000
lower Limit
0.11
upper Limit
9.32
value
4.05
denoms
counts
group Id
OG000
value
5
units
Participants
title
Dopamine concentration at 36 months off treatment
categories
measurements
group Id
OG000
lower Limit
0.91
upper Limit
11.24
value
2.56
denoms
counts
group Id
OG000
value
15
units
Participants
title
3,4-dihydroxyphenylacetic acid concentration at baseline
categories
measurements
group Id
OG000
lower Limit
0.82
upper Limit
9.91
value
1.62
denoms
counts
group Id
OG000
value
14
units
Participants
title
3,4-dihydroxyphenylacetic acid concentration at completion of treatment
categories
measurements
group Id
OG000
lower Limit
0.51
upper Limit
6.55
value
1.04
denoms
counts
group Id
OG000
value
15
units
Participants
title
3,4-dihydroxyphenylacetic acid concentration at 12 months off treatment
categories
measurements
group Id
OG000
lower Limit
0.31
upper Limit
6.70
value
1.52
denoms
counts
group Id
OG000
value
14
units
Participants
title
3,4-dihydroxyphenylacetic acid concentration at 24 months off treatment
categories
measurements
group Id
OG000
lower Limit
0.38
upper Limit
3.10
value
1.00
denoms
counts
group Id
OG000
value
9
units
Participants
title
3,4-dihydroxyphenylacetic acid concentration at 36 months off treatment
categories
measurements
group Id
OG000
lower Limit
0.12
upper Limit
13.94
value
2.38
denoms
counts
group Id
OG000
value
14
units
Participants
title
Hydroxytryptamine concentration at baseline
categories
measurements
group Id
OG000
lower Limit
0.06
upper Limit
15.01
value
2.01
denoms
counts
group Id
OG000
value
13
units
Participants
title
Hydroxytryptamine concentration at completion of treatment

denoms

counts
group Id
OG000
value
17
units
Participants

description

Concentrations of various neurotransmitters in cerebrospinal fluid were measured at 5 timepoints. The median concentration of each neurotransmitter at each time point was calculated and provided with a full range.

dispersion Type

Full Range

groups

description
Patients with neurotransmitter studies
id
OG000
title
Patients With Neurotransmitter Studies

param Type

MEDIAN

population Description

Eligible patients who had cerebrospinal fluid neurotransmitter studies performed. Seventeen patients had studies performed.

reporting Status

POSTED

time Frame

Baseline, at the completion of therapy, and every 12 months up to 36 months after off therapy date

title

Concentration of Cerebrospinal Fluid Neurotransmitters

type

SECONDARY

unit Of Measure

ng/ml

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice